Readline Biosciences Completes Over RMB 500 Million Series C Funding, Paving the Way for 'Kiloton-Scale' Production of Green Bioactive Ingredients

VCBeat has learned that Shenzhen REDLINE Biotechnology Co., Ltd. (hereinafter referred to as “REDLINE”) recently announced the completion of its Series C financing round, exceeding RMB 500 million.Green Pine Capital, Co-stone Capital, Changde Xingxin, Baiyin Kejian, Changde DeyuanCo-investment. The investors include managing entities of government or industrial funds such as the Shenzhen "20+8" Future Industry Fund, sub-funds of the National Science and Technology Achievement Transformation Guidance Fund, and the Changde Synthetic Biology Fund.

The Series C funding will be primarily allocated to capacity expansion and new product R&D. It is remarkable that the company has successfully closed its Series C round against the current headwinds of weak consumer demand and a relatively cautious capital market. This further demonstrates investors’ long-term optimism toward the synthetic biology sector, particularly for leading companies that have already achieved mass production, which are more likely to receive continued capital injections.

Synthetic biology is one of the most transformative technologies in the life sciences field of the 21st century, often referred to as the “Third Biological Revolution.” Built upon the foundational pillars of molecular biology, high-throughput sequencing, and fermentation engineering, synthetic biology integrates cutting-edge technologies such as artificial intelligence, bioinformatics, and high-throughput screening during its development. This approach transcends the traditional experimental paradigm of biological research, endowing biology with engineering and data-driven attributes, thereby transforming elusive biological organisms into rationally designable production tools.

Due to its disruptive and revolutionary impact on the manufacturing industry, synthetic biology has been regarded as a manifestation of national manufacturing competitiveness since its inception. In June 2021, the United States passed the U.S. Innovation and Competition Act of 2021, imposing restrictions on the export of synthetic biology technologies. China’s 14th Five-Year Plan for Bioeconomy Development explicitly calls for promoting technological innovation in synthetic biology and achieving breakthroughs in key technologies such as computational design of microbial strains for biomanufacturing, high-throughput screening, high-efficiency expression, and precise regulation. In January 2024, seven departments, including the Ministry of Industry and Information Technology, issued the Implementation Opinions on Promoting the Innovative Development of Future Industries, proposing to accelerate the industrialization of frontier technologies such as synthetic biology. Guided by national policies and driven by capital investment, domestic synthetic biology companies have sprung up in recent years. Emerging enterprises represented by universities, research institutes, and overseas-returnee elites, along with traditional giants represented by listed companies, have entered the field, creating a dynamic convergence. An increasing number of chemically synthesized molecules are now being produced through biomanufacturing. Driven by advanced technologies, the synthetic biology industry is gradually evolving into a strategic emerging industry.

However, the essence of competition in the high-tech sector is not a contest of technologies, but a rivalry among organizations that master leading-edge technologies. REDLINE has built its core corporate competitiveness around this very premise—the organization as the entity mastering technology—by proposing a visionary strategy driven by the dual engines of “technological innovation” and “management innovation,” and correspondingly designing a “dual-leadership” organizational structure. This top-level management architecture, originating from Silicon Valley, assigns operational responsibilities to the CEO and R&D oversight to the Chief Scientist, thereby striving for balanced decision-making. Entrepreneurial ventures founded by scientists are prone to becoming overly technology-centric, manifesting in an emphasis on technology over management, R&D over marketing, and the pursuit of technological leadership at the expense of customer needs, which often results in products that are critically acclaimed but commercially unsuccessful. This necessitates a CEO with industrial background and managerial experience to continuously correct the company’s course, realigning it with its economic mission and the value-creation logic centered on customers.

Moreover, technological innovation inherently carries significant uncertainty, while startups require a steady operational rhythm. This necessitates that CEOs employ systematic management methodologies to build organizational capabilities, thereby managing the various uncertainties throughout the R&D, mass production, and commercialization processes, and transitioning from accidental success to inevitable long-term sustainability.

Synthetic biology is a multidisciplinary industry. Through seven years of continuous investment, REDLINE has established China’s most comprehensive multidisciplinary biomanufacturing platform, equipped with capabilities in whole-cell synthesis, enzymatic catalysis, and chemical synthesis, along with mass production capacity. This integrated platform supports diversified product portfolios, enabling the company to flexibly leverage various synthetic technologies to rapidly respond to market demands. By capitalizing on the complementary advantages of these technologies, REDLINE achieves superior efficiency, quality, cost-effectiveness, and production capacity—advantages difficult to attain through traditional synthetic methods—thereby underpinning the sustained commercial success of its products.

REDLINE boasts an R&D team of over 200 members, more than 50% of whom hold master’s degrees or higher. Its R&D investment and scale rank among the top in China’s peer enterprises. Dozens of scientists, professors, doctoral supervisors, and national and local high-level talents from globally renowned pharmaceutical companies, universities, and research institutions are engaged in full-time research at REDLINE. The industrialization expert team possesses over 20 years of practical experience in chemical engineering, fermentation engineering, enzymatic catalysis, purification engineering, and plant design. The strategic combination of front-end and back-end talent enables the company to overcome industrialization barriers more rapidly. REDLINE has been recognized as a Postdoctoral Innovation Practice Base by both Shenzhen Municipality and Guangdong Province, and has been awarded the title of National “Specialized, Refined, Differential, and Innovative” Little Giant Enterprise. In 2024, the company was selected for the Shenzhen Overseas High-Level Talent Team program, and its R&D on key technologies for the biosynthesis of peptides and carbohydrates was approved as a Major Scientific and Technological Special Project of Shenzhen.

It is worth mentioning that,REDLINE is one of the first synthetic biology companies to introduce artificial intelligence (AI) technology into enzyme engineering. As early as 2020, the company established an AI team in the UK to conduct AI-assisted enzyme design and engineering. In recent years, REDLINE has systematically laid out its strategy around the core elements of AI—algorithms, computing power, and data—by establishing the ReAI4Bio platform. To date, the company has built more than 50 AI models and filed nearly 30 AI invention patents. It has also established its own computing center, equipped with over 10 supercomputing servers delivering a computational capacity of 200 trillion floating-point operations per second (TFLOPS). Furthermore, REDLINE has developed a proprietary protein database containing more than 5.2 billion entries and a high-quality private enzyme database with over 300,000 entries.Artificial intelligence has been applied to the company's internal R&D scenarios. By leveraging wet-lab data from typical industrial enzymes and integrating deep learning models, iterative training is conducted using combined dry- and wet-lab datasets, ultimately achieving precision in enzyme screening and engineering.

Technology and management act as dual drivers; any excellent, sustainable company must continuously summarize experiences and innovate in its management practices. During its years of rapid development, REDLINE has explored a distinctive management philosophy characterized by a dialectical understanding of key contradictions. This has been achieved through continuous trial and error, repeated calibration, and ongoing evolution, while extensively learning from the advanced management concepts and operational methodologies of leading enterprises and integrating these insights with its own entrepreneurial practices. First, after years of exploration, REDLINE has established its strategic positioning as a “Leader in Green Active Ingredients.” This strategic focus drives the enhancement of core corporate capabilities, determines priority in resource allocation based on annual strategic planning, and maintains dedication to long-term goals alongside flexibility in practical implementation paths. As the company’s operational focus has shifted from technology and mass production to marketing, it has gradually built organizational capabilities across R&D, production, and sales.

Startups in their growth phase are often driven by opportunism, leading to an irresistible impulse for expansion, primarily manifested through product diversification and vertical integration across the industrial chain. Blind diversification can blur operational focus and dilute resources, thereby affecting the company’s key objectives and operational rhythm. REDLINE has faced multiple strategic choices between “focus and diversification”: Should it become a platform-based or product-based enterprise? Should it adopt a blockbuster product strategy or a multi-product portfolio? Should it concentrate on a single domain or pursue multiple areas simultaneously? After several years of practice, the company chose to focus on its core competencies and extend into diversified products based on these capabilities. For instance, leveraging its green bio-manufacturing platform, REDLINE has achieved large-scale production of peptide raw materials such as glutathione, carnosine, and semaglutide. Recently, the company has also applied this platform capability to the mass production of ceramides, expanding its application fields from functional skincare to nutritional health, biopharmaceuticals, and animal nutrition. REDLINE understands the dialectical unity of focus and diversification from the perspective of core competencies, ensuring that high-quality resources and strategic efforts are continuously invested in building its core capabilities, while simultaneously meeting diverse customer needs through a diversified product portfolio to expand its market reach.

REDLINE’s core values can be distilled into four principles: “Customer Success, Symbiotic Growth, Embracing Change, and Long-Term Struggle.” These values represent an invisible yet tangible force within the company, influencing human behavior through a cultural “field.” This influence is manifested in several specific aspects:

First, core values determine the decision-making criteria for major trade-offs and key initiatives within the company.For instance, guided by the core value of “Customer Success,” the company has established a customer-centric product and service system. In the field of efficacy-based skincare, the company benchmarks against original research products, conducting systematic in vitro and human efficacy studies, investigations into influencing factors, stability testing, and consistency evaluations for raw materials. It was also the first to complete safety assessments for all its marketed products. The company chooses to forfeit a portion of its profits to collaborate with localized channel partners, providing customers with systematic technical support and higher-quality extended services. Through technological innovation, the company reduces the manufacturing costs of life molecules—represented by peptides, sugars, nucleotides, proteins, and lipids—thereby expanding the application scenarios of green active ingredients. To date, dozens of such ingredients, including semaglutide, “One Core, Three Factors, Eighteen Peptides,” and ceramides, have been widely adopted by nearly 1,000 clients across fields such as efficacy-based skincare, biopharmaceuticals, nutritional health, and animal nutrition.

Second, core values determine the internal order of a company’s organization, processes, and management systems.For example, guided by the core value of “symbiotic growth,” the company is organized into more than ten business centers based on functional divisions. These centers operate with a high degree of autonomy and report directly to the CEO. Internally, each center maintains a flat structure that emphasizes entrepreneurial roles while downplaying hierarchical distinctions. To prevent the formation of “departmental silos” among business centers, the company has also established Business Groups (BGs) and several project teams as cross-center deliberative and coordination mechanisms to drive R&D, marketing, production, and major strategic initiatives.

Third, the company encourages all entrepreneurs to “embrace change,” requiring heads of each center to be flexible in assuming or stepping down from roles and moving between frontline and support positions. This approach enables experienced managers to return to frontline roles while allowing high-performing entrepreneurs to rapidly step into new positions.Since its inception, the company has undergone more than ten organizational restructuring initiatives. Through multiple iterations, the corporate structure has become better aligned with the company’s current development strategy. By implementing regular organizational and personnel adjustments, the company continuously stimulates organizational vitality and reduces reliance on established hierarchies. Notably, since 2021, the company has been advancing comprehensive digitalization, which essentially leverages digital tools to transform individual capabilities into organizational capabilities through standardized business processes. For instance, all support processes within the company’s marketing system have been moved online, enabling deep integration of internal resources, streamlining internal communication, and achieving a closed-loop workflow from demand generation to delivery.

Fourth, REDLINE requires all entrepreneurs to acknowledge that the company’s success is the result of their long-term, unremitting efforts.Core values determine a company’s value orientation and evaluation criteria. As a strategic emerging industry, synthetic biology involves high technical integration complexity, with very limited cases of industrial application globally and even fewer instances of commercial success. The company requires all first-level managers to go to the business frontline, lead by example, and practice and interpret the core value of long-term struggle. The ability to embody corporate core values has become a key indicator for talent identification, selection, and incentive within the company. The company actively recruits outstanding entrepreneurs who share its commitment to joint efforts as partners; over 100 entrepreneur shareholders hold equity in the company, with cumulative capital contributions exceeding RMB 50 million, truly realizing the principle of “unified interests and concerted efforts.”

REDLINE’s management philosophy has yielded significant results in strategic execution, market expansion, talent acquisition, and adaptability to change. In 2023, it was recognized by Harvard Business Review as a High-Impact Innovation Team, making it one of the few startups selected that year. By late 2024, the company was named among Deloitte Shenzhen’s Fast 20 High-Tech High-Growth Companies, and in early 2025, it was further honored as one of Deloitte China’s Fast 50 High-Tech High-Growth Companies.

As a biomanufacturing enterprise, the company’s commercial success depends not only on technological iteration but also on production capacity alignment. In 2021, REDLINE established its production base in Baiyin, Gansu Province, achieving ten-ton-scale production of active ingredients. In 2022, the company commenced construction of its smart factory in Zhuhai, which became fully operational in the first half of 2024, with an annual output of nearly 200 tons of active ingredients for nutritional health and functional skincare. In November 2024, REDLINE’s thousand-ton-scale green active ingredient production base was settled in Shaoguan, with a planned annual output of 1,000 tons of green active ingredients such as peptides, sugars, and nucleotides, and an estimated annual output value exceeding RMB 2 billion. This includes a planned annual output of 2 tons of GLP-1 raw materials (such as semaglutide and tirzepatide), making it the largest biosynthetic GLP-1 raw material production base in China. The implementation of this project marks the company’s capacity leap from the hundred-ton to the thousand-ton scale, further consolidating its leading position in the field of green active ingredients.

Reviewing over two centuries of industrial development history, it is undeniable that technological progress is the fundamental force driving social evolution. However, at the micro level, the mindset that technological leadership alone can propel industrial development appears remarkably fragile in the face of a complex industrial society. Our understanding of technological advancement should return to a broader industrial perspective, examining its impact on production relations and economic structures. As Peter Drucker incisively argued forty years ago, there is a considerable lead time required for knowledge to be transformed into applicable technology and subsequently accepted by the market. Entrepreneurial management during this period is particularly critical, demanding managerial foresight and pragmatic market strategies to address the inevitable risks and uncertainties inherent in the industrialization of technological innovations.

Technology becomes obsolete, and products undergo iterations, but management philosophies endure. Confronted with the industrialization elements and commercialization pathways of innovative technologies, as well as the critical variable of whether products meet customer needs, what methodology should startups adopt? As a pioneer in the field of synthetic biology, REDLINE must explore these questions and provide answers.

Recommended Reading: “Continuously Launching Blockbuster Ingredients Such as S-Boisein, Peptides, and Semaglutide: How Does REDLINE Build a Green Active Ingredient Giant Through Synthetic Biology?”